Amag Pharmaceuticals Inc (NASDAQ:AMAG)’s Trend Up, Especially After Decreased Shorts

April 17, 2018 - By Peter Erickson

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Logo

Investors sentiment decreased to 0.9 in 2017 Q4. Its down 0.54, from 1.44 in 2017Q3. It worsened, as 29 investors sold AMAG Pharmaceuticals, Inc. shares while 53 reduced holdings. 24 funds opened positions while 50 raised stakes. 37.72 million shares or 5.64% less from 39.98 million shares in 2017Q3 were reported.
Moreover, Pnc Services has 0% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Tiaa Cref Management Llc owns 144,817 shares. Gru One Trading Limited Partnership has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Asset Mgmt holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 6,640 shares. 80,079 are held by Massachusetts Svcs Ma. Us Comml Bank De has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Federated Pa, a Pennsylvania-based fund reported 94,659 shares. State Of Tennessee Treasury Department holds 27,988 shares or 0% of its portfolio. Regions Financial, a Alabama-based fund reported 115 shares. 7,041 are held by State Of Alaska Department Of Revenue. Jane Street Grp Ltd Liability Company stated it has 12,115 shares. Panagora Asset Mngmt holds 0.02% or 306,041 shares in its portfolio. Livforsakringsbolaget Skandia Omsesidigt owns 46,600 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Management holds 50,000 shares. Zebra Capital Mgmt Ltd Liability Company holds 0.08% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 17,807 shares.

Since February 23, 2018, it had 0 insider buys, and 1 sale for $16,016 activity.

The stock of Amag Pharmaceuticals Inc (NASDAQ:AMAG) registered a decrease of 7.04% in short interest. AMAG’s total short interest was 9.37M shares in April as published by FINRA. Its down 7.04% from 10.08 million shares, reported previously. With 955,400 shares average volume, it will take short sellers 10 days to cover their AMAG’s short positions. The short interest to Amag Pharmaceuticals Inc’s float is 32.3%.

The stock increased 1.43% or $0.3 during the last trading session, reaching $21.25. About 510,900 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 16.25% since April 17, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $724.39 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 8 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. AMAG Pharmaceuticals had 17 analyst reports since October 23, 2017 according to SRatingsIntel. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Monday, March 5 by Jefferies. The company was maintained on Tuesday, February 27 by Cowen & Co. Morgan Stanley maintained the stock with “Overweight” rating in Friday, November 3 report. As per Thursday, November 2, the company rating was maintained by Cantor Fitzgerald. The firm has “Hold” rating by Piper Jaffray given on Wednesday, February 14. As per Friday, March 23, the company rating was maintained by FBR Capital. The firm earned “Hold” rating on Wednesday, February 14 by Cantor Fitzgerald. The company was upgraded on Thursday, February 15 by Janney Capital. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Thursday, January 18 by Piper Jaffray. Cantor Fitzgerald maintained it with “Hold” rating and $17.0 target in Thursday, February 1 report.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.